NCT03047993View on ClinicalTrials.gov

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

March 16, 2023

Study Completion Date

March 16, 2023

Conditions
Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-2Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Glutaminase Inhibitor CB-839

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03047993 - Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter